Wednesday, 12 Dec 2018

You are here

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abstract THU0222 reported data on 143 patients from a single clinic, ~50% had RA, and multi-switching between the etanercept originator and the biosimilar had no effect on retention of etanercept. In fact there may have even been a small protective effect of multi-switching on etanercept retention. Now it’s a single centre and its observational data so must be treated with a degree of caution but it’s an interesting result.

Another study from a large UK centre looked at the rate of flare after changing from the originator to the biosimilar and for etanercept found 4 out of 63 with RA flares after the change and 2 of 19 with SpA and 2 of 19 with PsA. For the infliximab biosimilar the flare rates was 2-4% across indications. Their conclusions were that the rate of flares was low and this supported single switch (THU0204)

Data from the TURKBIO registry on 614 patients showed that Remsima the infliximab biosimilar had better retention rates than Remicade over 5 years (THU 0218). There is also RABBIT registry data using Kaplan-Meier estimates showed that patients who were bionaive and were commenced on both the originator and biosimilar etanercept. The SB4 biosimilar (n = 250) was stopped around half the rate (14%) and the etanercept originator (n = 317) (THU0192).

So there seems to be an enlarging amount of data that is reassuring around switching patients to biosimilars and drug survival on biosimilars. But it is important to remember that registry and observational data has limitations so care has to be taken to put excessive weight on these types of results.

Add new comment

More Like This

Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks

Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks.

FDA Approves Biosimilar Rituximab for NHL, not RA

The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.

First FDA Approved Drug for HLH

The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.

Emapalumab (Gamifant), manufactured by Novimmune SA, may be used in all patients (including newborns and older children) "who have refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy," the FDA said.

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.